Track Annovis Bio, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Annovis Bio, Inc. ANVS · Stock Open Annovis Bio, Inc. in new tab

0.9261 USD
EPS
-1.75
P/B
-9.26
ROE
-703.68
Beta
1.35
Target Price
10.50 USD
Loading chart...
Key Metrics
Earnings dateApril 6, 2027
EPS-1.75
Book Value-0.10
Price to Book-9.26
% Insiders16.356%
Estimates
Forward P/E-1.08
Forward EPS-0.86
Target Mean Price10.50

DCF valuation

Model fair value for Annovis Bio, Inc. (ANVS)
Result
Sign in to run the valuation for ANVS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus None · mean target 10.50 USD (low 7.00, high 17.00) · as of 14 Nov 2026
Low 7.00
Mean 10.50
High 17.00
Price 0.9261
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Annovis Bio, Inc. Logo Annovis Bio, Inc. Analysis (ANVS)

United States Health Care Official Website Stock

Is Annovis Bio, Inc. a good investment? Annovis Bio, Inc. (ANVS) is currently trading at 0.9261 USD. Market analysts have a consensus price target of 10.50 USD. This suggests a potential upside from current levels.

Earnings Schedule: Annovis Bio, Inc. is expected to release its next earnings report on April 6, 2027. The market consensus estimate for Forward EPS is -0.86.

Investor FAQ

Does Annovis Bio, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Annovis Bio, Inc.?

Annovis Bio, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be April 6, 2027. The company currently has a trailing EPS of -1.75.

Company Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Exchange Ticker
ASE (United States) ANVS
FRA (Germany) 07X.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion